Headquartered in North Chesterfield, VA Fiscal year ends December NASDAQ: INDV indivior.com
Indivior Pharmaceuticals, Inc. (Nasdaq: INDV) is a specialty pharmaceutical company focused on treating opioid use disorder (OUD), which it describes as a chronic but treatable brain disease.
Its core product is SUBLOCADE, a long-acting injectable buprenorphine treatment. SUBLOCADE generated the large majority of the company's net revenue, and more than 583,000 U.S. patients have been prescribed it since launch. The company also sells sublingual buprenorphine and other legacy addiction-treatment products in the U.S. and in Rest of World markets.
It has discontinued promotional support for PERSERIS (a long-acting injectable risperidone for schizophrenia) and OPVEE (nalmefene nasal spray for opioid overdose).
In August 2026, Indivior agreed to an all-stock merger of equals with Supernus Pharmaceuticals to create a diversified, CNS-focused biopharmaceutical company. Shareholders approved the deal in October 2026. It is expected to close on November 2, 2026, after which the combined company will operate as Supernus, Inc. and trade on Nasdaq under the ticker SUPN. Updated
This is the last quarter Indivior reports as a standalone company, and it went out with a fifth straight EPS beat, again exceeding expectations. The Supernus merger closes November 2, with shares trading under the new symbol the next day.
Howard Marks just filed five equity positions that look nothing like a bull-market portfolio, and every one has moved sharply since he bought. The question now is whether his thesis still holds…
Indivior Pharmaceuticals, Inc. (Nasdaq: INDV) is a specialty pharmaceutical company focused on treating opioid use disorder (OUD), which it describes as a chronic but treatable brain disease. Its core product is SUBLOCADE, a long-acting injectable buprenorphine treatment.
24/7 Wall St.'s 12-month price target for INDV is $51.36, rated Buy. The Wall Street consensus target is $49.50. INDV price prediction →
